The Weekly Recap 6/12/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, achieve clinical milestones, receive awards, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Acorai

Won the CSI Congress Start-up Competition, including a $50K prize from the Jon DeHaan Foundation. The company is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. 

Aevice Health

Announced a new partnership with Parkway MediCentre to roll out one of Singapore’s first home-based pediatric asthma monitoring programs. Powered by the AeviceMD Monitoring System, the program allows clinicians to monitor a child’s respiratory health during sleep, the critical window when symptoms could be missed. 

CeQur

Closed a $100M Series E financing round to accelerate the commercial growth of the CeQur Simplicity™. CeQur Simplicity is a convenient, discreet, and injection-free wearable insulin patch that simplifies mealtime dosing.

CoapTech

Awarded a Build Our Future Grant for $478K from the Maryland Department of Commerce. The grant will help the company establish a local manufacturing hub for sterilely packaged medical devices, in partnership with The LaunchPort, at City Garage in Baltimore, including the development of sterile thermoform equipment.

EBR Systems

Announced that the Centers for Medicare & Medicaid Services initiated a National Coverage Determination process to evaluate uniform Medicare coverage for leadless left ventricular endocardial pacing used in cardiac resynchronization therapy (CRT). The milestone supports broader access to the company’s WiSE system, a wireless cardiac pacing device for heart failure, which delivers leadless left ventricular pacing and integrates with existing pacemakers, defibrillators, and CRT devices.

GT Medical Technologies

Closed an oversubscribed $100M Series E financing led by new investor Viking Global Investors, with participation from existing investors including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The funding will support expanded commercial and operational initiatives following the release of final data from the company’s ROADS randomized controlled trial.

Neuronoff

Implanted the first patient in a DOD-funded, double-blinded, randomized controlled clinical trial (RCT) of the Injectrode^®, evaluating the safety and efficacy of the Injectrode for the treatment of neurogenic bladder in individuals with spinal cord injury. The trial is being conducted at UT Health Houston under principal investigator Dr. Argy Stampas, MD, MS.

Onkos Surgical

Received FDA 510(k) clearance of the application of our NanoCept^® Antibacterial Technology to titanium implants in the ELEOS™ Limb Salvage System. By enabling NanoCept application to titanium, the company aims to broaden access to antibacterial implant technology across a wider portion of the ELEOS system.

Perimeter Medical Imaging AI

Selected for the latest round of the INOVAIT Canada Pilot Fund. The contribution will help the company advance next-generation AI capabilities for Claire™, the first FDA-approved AI-enabled imaging device for adjunctive use during breast cancer surgery.

PharmaSens

Enrolled the first patient in a clinical feasibility study of its all-in-one automated insulin patch pump system. The all-in-one pump pairs the Niaa insulin patch pump with a continuous glucose monitor (CGM) made by SiBionics.

Piccolo Medical

Acquired by Spectrum Vascular, a leading provider of vascular access and medication management products. Together, the two companies will accelerate commercialization, deepen integration with Spectrum Vascular’s existing catheter portfolio, and scale the next-generation navigation platform.

SpinaFX

Received FDA IDE approval for Triojection^®, enabling the initiation of a pivotal U.S. clinical trial evaluating intradiscal ozone/oxygen injection plus nerve root block versus nerve root block alone in patients with contained herniated lumbar discs who have failed conservative therapy. The study will assess a minimally invasive treatment approach designed to bridge the gap between conservative care and surgery, and evaluate the economic impact of adding Triojection to conventional treatments.

Star51 Capital

Closed its inaugural medtech venture fund, anchored by Abbott and Mayo Clinic Business Development as lead investors. The company invests in early and growth-stage companies spanning interventional therapies, diagnostics, monitoring, and the digitalization of healthcare.

THENA Capital

Closed its inaugural Fund I at £45M. Anchored by the British Business Bank’s Enterprise Capital Funds (ECF) program, and the first all-female General Partner-led fund to receive ECF backing, the company has deployed into five portfolio companies in its first year of operation: Plexāā, Salient Bio, Sanome, Heim, and Zonova.

Valcare Medical

Performed the first implant of AMEND TMVr Annuloplasty System at Oregon Health & Science University as part of the AMEND TS Early Feasibility Study. The AMEND System is designed to achieve the same effects as surgery for the treatment of mitral regurgitation, and offers a transcatheter procedure instead of traditional open-heart surgery.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.